Maki Umemura

The Japanese Pharmaceutical Industry (eBook, ePUB)

Its Evolution and Current Challenges

• Format: ePub

Produktbeschreibung

This book explores why Japan, despite being a world leader in many high technology industries such as automobiles and consumer electronics, is only a minor player in the global pharmaceutical industry. Japan provides a huge market for pharmaceuticals as the second largest consumer of prescription drugs after the United States, and is a massive importer of prescription drugs, relying on discoveries made elsewhere. This book charts the development of the industry, from the devastation resulting from the Second World War to its performance in the present day. Focusing in particular on antibiotics and anticancer drugs, the book analyses factors that have prevented Japan from leading the rapid advances in science and technology that have occurred globally over recent decades. Looking at the pharmaceutical industry, the book argues that the Japanese government's research and development policies were not sufficiently incentivising. It also shows how the nature of capitalism in Japan - which featured close relations between government and industry as well as between and within firms - was appropriate for nurturing industrial development in the immediate post-war decades, but became much less effective in later years.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Taylor & Francis eBooks
• Seitenzahl: 208
• Erscheinungstermin: 2. März 2011
• Englisch
• ISBN-13: 9781136828249
• Artikelnr.: 38273849

Autorenporträt

Maki Umemura is a lecturer in Japanese studies at Cardiff Business School, Cardiff University, UK.

Inhaltsangabe

1. Introduction: Why didn't Japan become a global leader in
pharmaceuticals? 2. A historical overview of Japan's pharmaceutical
industry 3. Developing a modern industry: The antibiotics sector 4. What
went wrong? The anticancer drug sector 5. Conclusion: Reconsidering Japan's
business in pharmaceuticals